A single-institutional brachytherapy experience in the management of esophageal cancer

Fabrini, Maria Grazia; Perrone, F.; Liguoro, M. de; Coppola, M.; Santi, Stefano; Solito, Biagio; Lencioni, Monica; Rossi, Mauro; Cionini, L.

doi:10.1016/j.brachy.2009.08.006

Cited by 7 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, other literature studies showed that CR after treatment completion may influence favourably the outcome. 19 In our series, the histological grading <3 and the dose ≥60 Gy showed only a trend for better DFS, whereas some literature studies observed a statistical significance of these parameters. 25 Acute toxicity was mainly of grade 1-2 (52%) and only in 4 cases (10%) was it of higher grade.…”

Section: Discussioncontrasting

confidence: 83%

See 1 more Smart Citation

Concomitant chemo-radiotherapy for unresectable oesophageal cancer: A mono-institutional study on 40 patients

Torrente

Turri

Deantonio

et al. 2012

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 83%

“…In other literature series, high dose-rate brachytherapy was used to either intensify the dose or palliate symptoms. 19,20 The overall response rate after chemo-radiation, assessed by endoscopy and CT, was 70% with 50% of CR. Other authors report response rates ranging from 38% to 96% with average CR rates of 60% and up to 96%.…”

Section: Discussionmentioning

confidence: 99%

Concomitant chemo-radiotherapy for unresectable oesophageal cancer: A mono-institutional study on 40 patients

Torrente

Turri

Deantonio

et al. 2012

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…Several studies have shown improved local control and durable alleviation of dysphagia by adding brachytherapy to EBRT in esophageal cancers [19, 20, 21]. The only existent randomized controlled trial in this context showed the superiority of brachytherapy over EBRT boost [22].…”

Section: Discussionmentioning

confidence: 99%

High-dose-rate intraluminal brachytherapy prior to external radiochemotherapy in locally advanced esophageal cancer: preliminary results

Safaei¹,

Ghalehtaki²,

Khanjani³

et al. 2017

jcb

View full text Add to dashboard Cite

PurposeDysphagia is a common initial presentation in locally advanced esophageal cancer and negatively impacts patient quality of life and treatment compliance. To induce fast relief of dysphagia in patients with potentially operable esophageal cancer high-dose-rate (HDR) brachytherapy was applied prior to definitive radiochemotherapy.Material and methodsIn this single arm phase II clinical trial between 2013 to 2014 twenty patients with locally advanced esophageal cancer (17 squamous cell and 3 adenocarcinoma) were treated with upfront 10 Gy HDR brachytherapy, followed by 50.4 Gy external beam radiotherapy (EBRT) and concurrent chemotherapy with cisplatin/5-fluorouracil.ResultsTumor response, as measured by endoscopy and/or computed tomography scan, revealed complete remission in 16 and partial response in 4 patients (overall response rate 100%). Improvement of dysphagia was induced by brachytherapy within a few days and maintained up to the end of treatment in 80% of patients. No differences in either response rate or dysphagia resolution were found between squamous cell and adenocarcinoma histology. The grade 2 and 3 acute pancytopenia or bicytopenia reported in 4 patients, while sub-acute adverse effects with painful ulceration was seen in five patients, occurring after a median of 2 months. A perforation developed in one patient during the procedure of brachytherapy that resolved successfully with immediate surgery.ConclusionsBrachytherapy before EBRT was a safe and effective procedure to induce rapid and durable relief from dysphagia, especially when combined with EBRT.

show abstract

“…Following upfront surgery, combined radio-chemotherapy with temozolomide according to the Stupp regimen represents the standard post-operative therapy. Following the diagnosis of GBM recurrence, some patients may bene t from second surgery, as well as second-line chemotherapy or re-irradiation; however, there is currently no standard therapy for GBM recurrence and the clinical decision-making process lacks clinical biomarkers for guidance [2,[5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma

Pasqualetti¹,

Montemurro

Desideri

et al. 2021

Acta Neurol Belg

View full text Add to dashboard Cite

Background. The impact of different patterns of glioblastoma (GBM) recurrence has not yet been fully established in patients suitable for a second surgery. Through the present observational study carried out at Pisa University Hospital, we aimed to examine the impact of different patterns of GBM failure on patients' survival and second surgery outcomes. Methods. Overall survival was assessed according to clinical characteristics, including pattern of recurrence, in a prospective cohort of recurrent GBM patients. Survival curves were calculated using the Kaplan-Meier method and the log-rank test was applied to evaluate the differences between curves.Results. Contact with ventricles, a second surgery and meningeal spread had a statistically impact on patient survival after the diagnosis of GBM recurrence (P=0.032, P=0.019 and P<0.01, respectively).Patients with local recurrence had better survival than patients with non-local ones, 24.1 versus 18.2 months, respectively (P=0.015, HR=1.856 (1.130 -3.050). Considering the cohort as a whole, the second surgery conferred an advantage in recurrent survival respect to non-operated patients. However, this advantage was more evident in patients with local recurrence (P=0.002 with HR 0.212 (95% CI 0.081-0.552) and P=0.029 with HR=0.522 (95% CI 0.291-0.936), respectively).Conclusions. The local recurrence pattern could be a promising eld of interest for patients with recurrent GBM suitable for a second surgery.

show abstract

A single-institutional brachytherapy experience in the management of esophageal cancer

Cited by 7 publications

References 20 publications

Concomitant chemo-radiotherapy for unresectable oesophageal cancer: A mono-institutional study on 40 patients

Concomitant chemo-radiotherapy for unresectable oesophageal cancer: A mono-institutional study on 40 patients

High-dose-rate intraluminal brachytherapy prior to external radiochemotherapy in locally advanced esophageal cancer: preliminary results

Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma

Contact Info

Product

Resources

About